Stay updated on SB3 vs. Herceptin® in HER2+ Breast Cancer Clinical Trial

Sign up to get notified when there's something new on the SB3 vs. Herceptin® in HER2+ Breast Cancer Clinical Trial page.
Latest website image capture
Clouds background image

Latest updates to the SB3 vs. Herceptin® in HER2+ Breast Cancer Clinical Trial page

  1. Check
    6 days ago
    Change Detected
    Summary
    The NIH banner announcing terminology changes related to the agency transition is no longer displayed. The page continues to show a 403 Forbidden error rather than the study record.
    Difference
    1%
    Check dated 2026-11-08T00:55:39.000Z thumbnail image
  2. Check
    13 days ago
    Change Detected
    Summary
    The site footer shows an updated revision number, while the page remains a 403 Forbidden error.
    Difference
    0.2%
    Check dated 2026-10-31T19:09:34.000Z thumbnail image
  3. Check
    20 days ago
    Change Detected
    Summary
    A site-wide notice announces that NIH is transitioning to use “Super Intelligence” (SI) in place of “Artificial Intelligence” (AI), with a link to updates and FAQs.
    Difference
    1%
    Check dated 2026-10-24T22:22:03.000Z thumbnail image
  4. Check
    27 days ago
    Change Detected
    Summary
    The footer revision identifier changed from v3.7.1 to v3.7.2 on the error page.
    Difference
    0.2%
    Check dated 2026-10-17T22:24:00.000Z thumbnail image
  5. Check
    34 days ago
    Change Detected
    Summary
    The footer revision label changed from v3.7.0 to v3.7.1, while the page continues to display a 403 Forbidden error.
    Difference
    0.2%
    Check dated 2026-10-10T22:17:35.000Z thumbnail image
  6. Check
    55 days ago
    Change Detected
    Summary
    Study page now renders as a 403 Forbidden error, replacing the detailed study information with a generic error screen. A Home link is provided, and the footer shows Revision: v3.7.0.
    Difference
    17%
    Check dated 2026-09-19T20:22:17.000Z thumbnail image

Stay in the know with updates to SB3 vs. Herceptin® in HER2+ Breast Cancer Clinical Trial

Enter your email address, and we'll notify you when there's something new on the SB3 vs. Herceptin® in HER2+ Breast Cancer Clinical Trial page.